Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 06/03/2026 GMT			5-day change	1st Jan Change
2.990 ^SEK	+2.75%		-3.86%	+1.01%

02-20	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-20	Initiator Pharma reports Q4 net revenue of DKK 0.00	RE

Initiator Pharma Secures European Patent for Female Sexual Dysfunction Therapy

Published on 02/18/2026 at 04:40 pm GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Initiator Pharma A/S

02-20	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-20	Initiator Pharma reports Q4 net revenue of DKK 0.00	RE
02-20	Initiator Pharma Q4 operating loss widens to DKK 7 mln	RE
02-18	Initiator Pharma Secures European Patent for Female Sexual Dysfunction Therapy	MT
02-18	Initiator Pharma granted European patent for pudafensine in FSD	RE
12-23	Initiator Pharma A/S Initiates Patient Enrollment in Phase IIa Study	CI
11-21	Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-21	Initiator Pharma Q3 operating loss at DKK 4.3 mln	RE
11-03	Initiator Pharma gets UK CTA approval for phase 2a study	RE
11-03	Initiator Pharma A/S Receives UK CTA Approval to Initiate Phase 2a Study in Vulvodynia	CI
03/09/25	Initiator Pharma Applies to Initiate Phase 2a Study in Vulvodynia	CI
22/08/25	Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
22/08/25	Initiator Pharma Q2 EBIT loss narrows to DKK 3.8 mln	RE
28/05/25	Initiator Pharma Updates Timeline For Rights Issue	RE
23/05/25	Initiator Pharma A/S Elects Göran Ando as Members of the Board	CI

Chart Initiator Pharma A/S

Duration

Period

INIT: Dynamic Chart

Company Profile

Initiator Pharma A/S is a Denmark-based company engaged in the biotechnology sector. The Company focuses on developing drugs for treatment of erectile dysfunction.

Employees

Sector

Biotechnology & Medical Research

Calendar

05-08 - Earnings release - Q1 2026

More about the company